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Summary Background Targeting the cell-surface receptor
EphA2, which is highly expressed in some solid tumors, is a
novel approach for cancer therapy. We aimed to evaluate the
safety profile, maximum tolerated dose (MTD), pharmaco-
kinetics, and antitumor activity of MEDI-547, an antibody
drug conjugate composed of the cytotoxic drug auristatin
(toxin) linked to a human anti-EphA2 monoclonal antibody
(1C1), in patients with solid tumors relapsed/refractory to
standard therapy. Methods In this phase 1, open-label study
with planned dose-escalation and dose-expansion cohorts,
patients received a 1-h intravenous infusion of MEDI-547
(0.08 mg/kg) every 3 weeks. Results Six patients received
0.08 mg/kg; all discontinued treatment. Dose escalation was
not pursued. The study was stopped before cohort 2 enroll-
ment due to treatment-related bleeding and coagulation
events (hemorrhage-related, n03; epistaxis, n02). There-
fore, lower doses were not explored and an MTD could
not be selected. The most frequently reported treatment-
related adverse events (AEs) were increased liver enzymes,
decreased hemoglobin, decreased appetite, and epistaxis.
Three patients (50%) experienced treatment-related serious
AEs, including conjunctival hemorrhage, pain (led to study
drug discontinuation), liver disorder, and hemorrhage. Best
response included progressive disease (n05; 83.3%) and
stable disease (n01; 16.7%). Minimal or no dissociation of
toxin from 1C1 conjugate occurred in the blood. Serum
MEDI-547 concentrations decreased rapidly, ~70% by
3 days post-dose. No accumulation of MEDI-547 was ob-
served at 0.08 mg/kg upon administration of a second dose
3 weeks following dose 1. Conclusions The safety profile of
MEDI-547 does not support further clinical investigation in
patients with advanced solid tumors.
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Introduction
Ephrin type-A receptor 2 (EphA2), a member of the Eph
family of receptor tyrosine kinases, is involved in develop-
mental cell-to-cell interactions and cell migration processes,
including angiogenesis and neural crest cell migration [1, 2].
These events occur through the interaction of the Eph
receptors with their ligands, the ephrins, that are anchored
to the membrane of adjacent cells. While EphA2 is
expressed at relatively low levels in normal adult tissues
[1, 3], it is overexpressed in a number of carcinomas,
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including ovarian, endometrial, and cervical cancers; mela-
noma; and gliomas [4–16]. EphA2 overexpression in sever-
al types of cancers has been correlated with poor patient
outcome [17–20]. Collectively, these findings suggest that
EphA2 may be an ideal tumor target for cancer therapy. In
addition to serving as a direct target, EphA2 could be used
as a cancer-related protein for antibody-targeting therapy,
particularly antibody-drug conjugate (ADC)-based thera-
pies, in which chemical toxins or radioligands are covalently
added to the antibody structure [21].
MEDI-547 is an ADC composed of a human immuno-
globulin (Ig) G1 monoclonal antibody directed against
EphA2 (known as 1C1) and conjugated on cysteine residues
to an auristatin derivative linker-toxin maleimidocaproyl-
monomethyl auristatin phenylalanine (mcMMAF) [22].
The antibody has no antitumor effects when unconjugated
[22]; thus, it was intended to be used to deliver highly toxic
chemotherapy directly to EphA2-expressing cancer cells.
Auristatin is a microtubule inhibitor that binds to the vinca
alkaloid-binding domain, and has been shown to exhibit
potent anticancer effects in preclinical and clinical studies
[11, 23, 24]. MEDI-547 binds human, cynomolgus monkey,
mouse, and rat EphA2 with similar binding affinities via the
highly conserved extracellular domain [7, 22] (MedI-
mmune, LLC, data on file). Upon internalization of
MEDI-547, cysteine (cys)-mcMMAF is released from 1C1
by lysosomal degradation of the antibody component, in-
ducing cell cycle arrest at the G2 – M border, microtubule
disruption, and apoptotic cell death [7, 22].
A primary concern for any new targeted cancer therapy is
the range and sensitivity of potentially susceptible tissues,
both normal and malignant. A Good Laboratory Practice-
compliant tissue cross-reactivity study of MEDI-547 con-
ducted on a full panel of normal human tissues from 3
donors demonstrated rare, weak staining of the epithelium
of tonsilar crypts and esophageal mucosa, and occasional,
weak cytoplasmic staining of placental trophoblastic epithe-
lium. All other tissues were negative [25]. In tumor xeno-
graft studies in nude mice, MEDI-547 inhibited the growth
of EphA2-expressing tumors with no obvious adverse
effects [7, 15, 22]. The intravenous dose at which antitumor
activity was observed in mice was 1–3 mg/kg [22]. Based
on preclinical efficacy studies, the anticipated efficacious
dose in humans was 1.2 mg/kg once every 3 weeks (q3wks)
or 0.405 mg/kg every week (qwk).
Based on these and other preclinical results, a phase 1,
open-label first-in-human study was conducted to investi-
gate the safety profile, tolerability, and maximum tolerated
dose (MTD) of MEDI-547 in patients with relapsed or
refractory solid tumors. Secondary objectives included eval-




Patients at least 18 years of age and with a life expec-
tancy >16 weeks were eligible for enrollment into the
study if they had a histologically confirmed malignant
solid tumor thought to be associated with increased
expression of EphA2 (endometrial, breast, ovarian, prostate,
non-small cell lung, colon, esophageal, gastric, and bladder
cancers, renal cell carcinoma, melanoma) [4–15], relapsed or
refractory to standard therapy, and an Eastern Cooperative
Oncology Group (ECOG) performance status score of 0–2.
Laboratory criteria included absolute neutrophil count ≥1,500/
μL, platelet count ≥100,000/μL, hemoglobin >10.0 g/dL,
serum creatinine ≤1.5 times the upper limit of normal (ULN)
or calculated creatinine clearance >50 mL/min, serum biliru-
bin ≤2 times the ULN, alkaline phosphatase <3 times the
ULN, and aspartate aminotransferase (AST) and alanine ami-
notransferase (ALT) ≤3 times the ULN. Prothrombin time,
partial thromboplastin time, and international normalized ratio
were required to be within normal institutional limits.
Patients with active infectious disease, known brain metas-
tases, or a serious illness thought to interfere with the protocol
were excluded from the study, as were those who were treated
with other investigational drugs or had participated in another
clinical trial within 30 days before the start of therapy or
concomitantly with this trial. Patients with a known secondary
malignancy that required therapy, abnormal hematologic val-
ues, impaired renal or liver function were also excluded, as
were those patients who had any evidence of hematemesis,
melena, hematochezia, ≥ grade 2 hemoptysis, or gross hema-
turia or who were on anticoagulant therapy for thromboem-
bolic disorders or prophylactic reasons.
Concomitant medications from 30 days prior to the first
dose through 30 days after the last dose of MEDI-547 were
minimized to those medications necessary for management of
active comorbid diseases and symptoms related to cancer
burden or treatment of side effects. The following medications
were considered exclusionary: (1) investigational agents for
anticancer treatment or supportive care; and (2) any antitumor
therapy other than MEDI-547, such as cytostatic and/or cyto-
toxic drugs, hormonal therapy, radiation therapy, immunother-
apy, or any biological response modifiers.
The protocol was reviewed and approved by the Institutional
Review Board of the two participating sites. Written informed
consent was obtained from each patient before study entry.
Study design
Patients were to receive MEDI-547 as a 1-h intravenous
(IV) infusion once q3wks or qwk for 3 consecutive weeks
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until unacceptable toxicity, progressive disease, initiation of
alternative anticancer therapy, or other reasons for with-
drawal. The study included a standard 3+3 dose-escalation
design. The starting dose of 0.08 mg/kg was selected as 1-
tenth the highest non-severely toxic dose (5 mg/kg) in the
rat, which was determined to be the most sensitive species in
toxicity studies. Subsequent cohort dose levels were to be
increased by 50% to 10 mg/kg or until determination of the
MTD. Enrollment into the weekly dosing cohorts would
begin after the 0.27 mg/kg dose level in the q3wks schedule
was considered to have no safety concerns based on dose-
escalation rules.
Safety profile and tolerability assessments
Adverse events (AEs) were graded according to the National
Cancer Institute Common Terminology Criteria for Adverse
Events (CTCAE) version 3.0. Physical examination, vital
signs, electrocardiogram, performance status, laboratory eval-
uations including coagulation studies, and AE and serious AE
(SAE) monitoring were used to assess safety. For non-
hematologic toxicities, dose-limiting toxicity (DLT) was de-
fined as any ≥grade 3 toxicity except grade 3 or 4 nausea and
vomiting for <24 h and grade 3 non-hematologic laboratory
abnormalities that resolve to grade 1 within 7 days. For
hematologic toxicities, DLTwas defined as grade 4 neutrope-
nia for >7 days, grade 4 febrile neutropenia (or grade 3
requiring antibiotics), or grade 4 platelets (<25,000/μL) at
any time. DLTs were assessed within 21 days after treatment
initiation with MEDI-547 for cycle 1. The MTD was to be
defined on the basis of DLT observed during the first cycle of
treatment. If 1 of 3 patients experienced a DLT in the first
cycle, an additional 3 patients were to be enrolled. If ≥2
patients at the same dose level experienced a DLT, the MTD
would be exceeded and a total of 6 patients would be treated at
the preceding dose. If ≤1 of 6 patients experienced a DLT, then
this dose level would be the MTD. Once the MTD was
determined, the study planned to suspend enrollment into
higher dose cohorts, and expand the MTD patient cohort.
Immunogenicity evaluation
Blood samples were collected before infusion of MEDI-547
and at the end of treatment for determination of anti-MEDI-
547 antibody levels. The immunogenicity assay for measuring
anti-MEDI-547 antibodies was built upon a bridging format
using electrochemiluminescence (ECL) technology platform
developed by Meso Scale Discovery (MSD). Briefly, biotiny-
lated MEDI-547 and ruthenylatedMEDI-547 were allowed to
form a complex with the analyte (anti-MEDI-547 antibodies)
contained in the serum samples during an overnight incuba-
tion. The anti-drug antibodies (ADA) bridged complexes were
captured by the streptavidin-coated MSD plate and detected
by MSD Sector Imager.
Pharmacokinetic evaluation
Blood samples were collected for measurement of MEDI-
547 antibody-drug conjugate, MEDI-547 ADC + 1C1 (total
1C1, unconjugated and conjugated), cys-mcMMAF (the
linear form of the toxin component), and cyclic cys-
mcMMAF (the cyclic form of the toxin component) con-
centrations following administration of MEDI-547 ADC.
Two enzyme-linked immunosorbent assays (ELISA) were
used to measure the serum concentrations of the IgG-cys-
mcMMAF conjugate (ADC) and the IgG (total 1C1). The
lower limit of quantification (LLOQ) was 0.5 μg/mL for
both ADC and 1C1. A validated liquid chromatography-
mass spectrometry (LC/MS) assay was used to determine
the plasma levels of cys-mcMMAF and cyclic cys-
mcMMAF. Briefly, the analysis of cyc-mcMMAF and cyc-
mcMMAF cyclic was conducted on an HPLC system inter-
faced with a mass spectrometer, using turbospray ionization
in the positive ion mode. The analyte and internal standard
(m+7 cyc-mcMMAF) were detected by multiple reactions.
The LLOQ was 2 ng/mL for both cys-mcMMAF and cyclic
cys-mcMMAF. Serum and plasma concentrations were
summarized. Pharmacokinetic parameters were not estimat-
ed due to limited concentration data at low dose (0.08 mg/kg
by 1-h infusion q3wks).
Clinical activity assessment
Tumor assessments were performed at screening and approx-
imately every 6 weeks (2 cycles) after the first dose of MEDI-
547. Disease response was assessed by tumor measurements,
evaluated according to Response Evaluation Criteria in Solid
Tumors version 1.0 [26] and defined as a complete response,
partial response, stable disease, or progressive disease.
Statistical analyses
Safety, efficacy, and pharmacokinetic characteristics were
analyzed in an exploratory and descriptive manner. All
patients who received at least one dose of MEDI-547 were
included in the efficacy and safety analyses.
Results
Patient population
The study was conducted at two clinical sites in the United
States between August 4, 2009, and January 26, 2010. A
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total of 6 patients were enrolled, all in the 0.08 mg/kg q3wks
treatment group. All patients discontinued treatment due to
progressive disease (n04), AEs (n01), or planning to initi-
ate a different treatment (n01). This last patient was also
assessed as having progressive disease. Four patients dis-
continued the study due to withdrawal of consent and 2
patients discontinued for other reasons (notification of study
closure and planning to initiate other treatment). All patients
were women, most were Caucasian, and the median age was
63 years (range: 49–75). All patients previously had chemo-
therapy; most previously had surgery and had experi-
enced radiation, hormonal, or another type of cancer
therapy (Table 1). The median number of prior chemo-
therapy regimens was 3 (range: 1–8). The primary tu-
mor types included endometrial (n03), breast (n01),
colon (n01), and ovarian (n01) cancer. All patients
had metastatic cancer at study entry.
Safety profile and tolerability
All 6 patients were exposed to MEDI-547 at a dose of
0.08 mg/kg once every 3 weeks. Four patients received 1
treatment cycle and 2 patients received 2 treatment cycles.
All patients experienced at least one AE, with a total of 70
events reported. The most common (≥3 patients) AEs
reported were increased ALT and decreased serum albumin
concentrations (50% each). Five patients (83.3%) experi-
enced at least one treatment-related AE, with a total of 36
such events reported (Table 2). The majority of treatment-
related AEs were grade 1 (23 AEs) and 2 (12 AEs) in
severity; one was classified as grade 3 (pain). Four patients
(66.7%) experienced 5 serious AEs (SAEs): conjunctival
hemorrhage, constipation, pain, liver disorder, and hemor-
rhage. With the exception of constipation, these SAEs,
reported in 3 patients (50%), were considered by the inves-
tigator to be treatment-related; 1 SAE (pain) led to discon-
tinuation of the study drug in 1 patient. No deaths occurred
during the study.
Five of 6 patients (83.3%) experienced bleeding and coag-
ulation events. Three patients had hemorrhage-related events,
and 2 patients reported epistaxis. Three patients had bleeding/
coagulation AEs that were also SAEs. The occurrence of these
bleeding and coagulation events in the first dose cohort was
the reason this study was closed early (Table 3).
Immunogenicity
All six patients had immunogenicity assessments conducted
at the end of treatment, all of which were negative for anti-
MEDI-547 antibodies. One of these patients tested positive
(titer020) at cycle 1, day 1 pre-dose, at a level just above the
LLOQ (titer010).
Pharmacokinetics
Following IVadministration of MEDI-547 ADC at 0.08 mg/
kg by 1-h infusion every 3 weeks, serum MEDI-547 ADC
Table 1 Previous treatments







a100% were in a neoadjuvant/adjuvant setting
b66.7% were in a neoadjuvant/adjuvant setting
cRadiation therapy was palliative care in 1 patient
Table 2 Treatment-related adverse eventsa
Adverse event No. (%) of patients (N06)
ALT increased 3 (50.0)
AST increased 2 (33.3)
Hemoglobin decreased 2 (33.3)
Decreased appetite 2 (33.3)
Epistaxis 2 (33.3)
Angina pectoris 1 (16.7)
Conjuctival hemorrhage 1 (16.7)
Eye pain 1 (16.7)




Liver disorder 1 (16.7)
Blood albumin decreased 1 (16.7)
Blood alkaline phosphatase increased 1 (16.7)
Blood glucose increased 1 (16.7)
Blood magnesium increased 1 (16.7)
Blood sodium increased 1 (16.7)
Platelet count decreased 1 (16.7)




Pleural effusion 1 (16.7)
Hemorrhage 1 (16.7)
ALT alanine aminotransferase; AST aspartate aminotransferase; WBC
white blood cell
aRelated is defined as possibly, probably, or definitely related to study
drug
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concentrations were generally similar to MEDI-547 ADC +
1C1, indicating minimal or no dissociation of toxin from
1C1 conjugate in the blood. Plasma concentrations for cys-
mcMMAF and cyclic cys-mcMMAF were undetectable
(LLOQ02 ng/mL) at all time points in all patients. At
0.5 h after the end of infusion, serum concentrations of
MEDI-547 ADC and MEDI-547 ADC + 1C1 in all 6
patients were measurable, and the mean values were 2.140
and 2.058 μg/mL, respectively. Serum concentrations of
MEDI-547 ADC and MEDI-547 ADC + 1C1 decreased
approximately 70% by 3 days post-dose, and the mean
values were 0.670 and 0.728 μg/mL, respectively. Serum
concentrations for both ADC and ADC + 1C1 were below
detection limit (LLOQ00.5 μg/mL) 7 days post-dose.
Two patients received a second dose of MEDI-547
3 weeks later with mean serum concentration of 2.175 μg/
mL for both MEDI-547 ADC and MEDI-547 ADC + 1C1 at
0.5 h after the end of infusion, indicating no accumulation at
this dose level and with a 3-week dosing interval.
Clinical activity
Five patients had an overall response of progressive disease
and 1 patient had an overall response of stable disease. No
complete or partial tumor responses were observed.
Discussion
This was a phase 1, open-label study that was intended to
assess a dose of IV MEDI-547 q3wks in patients with solid
tumors relapsed or refractory to standard therapy. Six
patients were accrued with 4 receiving only one cycle of
treatment. The study was stopped before enrollment of dose-
escalation cohort 2 due to bleeding and coagulation events
that occurred in 5 of 6 patients. The perceived overall risk of
a serious bleeding event at higher doses was felt to be
sufficiently high that continued clinical evaluation was
deemed unsafe. Based on animal studies, we expected that
antitumor activity would begin to occur at 1.2 mg/kg q3wks
(dose level 8). Thus, the likelihood of reaching an effica-
cious dose without unacceptable toxicity was low because
of the types and severity of toxicity that were observed at the
starting dose, and the magnitude of the difference between
starting and expected efficacious doses.
Bleeding and coagulation events were consistent with the
disease profile and may have been associated with disease
progression, but MEDI-547 was also a likely cause of these
events. The patient with an SAE of hemorrhage was admit-
ted to the emergency room after reporting hemoptysis; she
had numerous large pulmonary metastases. However, her
hemoptysis stopped with discontinuation of MEDI-547, de-
spite continued growth of the pulmonary metastases.
The appearance of clotting abnormalities was not unex-
pected based on the preclinical toxicology findings, but the
potential severity was unknown in a clinical setting. The
bleeding and coagulation events observed in humans showed
some similarities to those evident in rats and monkeys [25]. In
all three species, increased activated partial thromboplastin
time, increased fibrinogen/fibrin degradation product, and
increased fibrin D-dimer were reported. Monkeys had red/
blood discharge from the nose, mouth, gums and/or anus,
whereas two patients experienced epistaxis and one patient
experienced an oral cavity hemorrhage. Preclinical toxicology
studies in the monkey identified disseminated intravascular
coagulation (DIC) as the DLT. The events observed in humans
were considered to be consistent with the preclinical findings,
in particular to the observation of DIC.
The dose used in the clinical study was 10-fold lower
than the highest non-severely toxic dose predicted based on
extrapolations from rat studies (MedImmune, LLC, data on
file), and no evidence of drug accumulation after the admin-
istration of a second dose was apparent.
Although auristatin is an effective cytotoxic agent for the
treatment of many types of cancers, it exposes patients to a
considerable risk for peripheral neuropathies, as do other
Table 3 Bleeding- and coagulation-related adverse events
Adverse event Cycle (C)/Day (D) Severity Relationship to MEDI-547 SAE
Paina C1/D22 Grade 3 Possible Yes
Liver Disordera C1/D22 Grade 2 Possible Yes
Conjunctival Hemorrhage C1/D8 Grade 1 Possible Yes
Epistaxis C1/D3 Grade 1 Possible No
Mouth Hemorrhage C1/D4 Grade 1 Possible No
Epistaxisb C1/D7 Grade 1 Possible No
Hemorrhageb C1/D9 Grade 2 Possible Yes
SAE serious adverse event
a SAEs in the same patient
b SAEs in the same patient
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therapies using microtubule-stabilizing agents [27, 28]. Pe-
ripheral neuropathy and associated adverse events were
reported in 36% of patients in a recent phase 1 study that
treated CD30-positive lymphoma patients with brentuximab
vedotin, another ADC containing auristatin [29]. Most ad-
verse events were reported for patients who were treated
with 1.8 or 2.7 mg/kg. The adverse events observed in
patients treated with MEDI-547, however, were of a differ-
ent class than those observed in patients treated with bren-
tuximab vedotin (hematologic events vs. neuropathies) and
were observed following treatment with lower doses. Rash,
possibly due to the expression of glycoprotein non-
metastatic melanoma protein B (GPNMB) in healthy skin,
was the most common toxicity reported after treatment with
glembatumumab, another ADC containing monomethyl
auristatin E that is being evaluated for the treatment of
GPNMB-expressing breast cancers and melanomas [30].
Neutropenia, another predictable AE associated with auri-
statin, was also reported as a grade 3 DLT in clinical studies
of glembatumumab [11].
Nonspecific toxicity from auristatin is unlikely to explain
the observed events in the present study, because serum
MEDI-547 concentrations were generally similar to
MEDI-547 + 1C1 concentrations, indicating minimal or no
dissociation of toxin from the antibody in the blood. Fur-
thermore, cys-mcMMAF and cyclic cys-mcMMAF were
not detected in the serum of patients. Based on these data
and the experiences with brentuximab vedotin and glemba-
tumumab, the antibody component of the ADC (1C1) prob-
ably underlies the MEDI-547 toxicity observed in the
present study.
Previous studies did not support the possibility that
MEDI-547 targeted EphA2 in normal tissues. Preclinical
evaluation found no reactivity of MEDI-547 in target organs
of the rat or monkey (MedImmune, LLC, data on file) [25].
MEDI-547 did bind non-specifically to most target tissues at
the highest doses administered, and toxicities were most
commonly hyperplasias, increased mitotic figures, and ne-
croses. Non-specific binding was more likely to have oc-
curred in these preclinical models because the top dose used
in the toxicity study was approximately 12-fold greater than
the efficacious dose required for a rat tumor model, and
60-fold higher than the starting dose in the clinical study
(MedImmune, LLC, data on file) [25]. Another study
also suggested that potential targeting of MEDI-547 to
normal tissue was minimal, with preferential distribution
to tumors and no accumulation in normal mouse or rat
tissues [31]. Targeting of MEDI-547 to normal tissues
must be reassessed, however, in light of the results of
this clinical study. Previous preclinical analyses of human
tissue cross-reactivity demonstrated weak membrane
staining of the epithelium of tonsilar crypts and esopha-
geal mucosa, and weak cytoplasmic staining of placental
trophoblastic epithelium (MedImmune, LLC, data on
file). The weak tissue reactivity was considered rare
and not significant enough to warrant cessation of drug
development in the preclinical stage. It is now important
to reconsider these findings, as these tissues may repre-
sent targets for MEDI-547 underlying the AEs experi-
enced by the patients in this study.
Despite the results of this study, EphA2 remains a poten-
tial target for cancer therapeutics, because it is overex-
pressed in a number of cancer types, and this is correlated
with poor patient outcome [17–20]. A wide range of thera-
peutic strategies are under development using monoclonal
antibodies, immunoconjugates, small-molecule antagonists,
adenovirus vectors, immunotherapy, RNA interference, vac-
cination, and nanoparticles [32]. For example, dasatinib, an
orally active small-molecule tyrosine kinase inhibitor that
has potent inhibitory activity against EphA2 [33], is being
evaluated in clinical studies for the treatment of squamous cell
carcinoma (ClinicalTrials.gov identifier: NCT00563290), in
combination with chemotherapy for endometrial cancer (Clin-
icalTrials.gov identifier: NCT01440998), in combination with
radiotherapy for glioblastoma (ClinicalTrials.gov identifier:
NCT00895960), and in combination with bevacizumab for
patients with solid tumors (ClinicalTrials.gov identifier:
NCT00792545). Another approach using a combination ther-
apy of EphA2 small interfering RNA (siRNA) with the che-
motherapeutic drug paclitaxel was more effective in inhibiting
growth of HeyA8 or SKOV3 orthotopic ovarian tumors in
mice than was treatment with the control siRNA and
paclitaxel [34]. In yet another approach, nanoshells target-
ing EphA2 were used to kill EphA2-overexpressing PC-3
cells but not EphA2-deficient human dermal fibroblast
cells [35]. The results observed so far with some of these
therapeutic approaches support EphA2 as a cancer target.
In addition, the favorable clinical data reported using
ADCs such as brentuximab vedotin and glembatumumab
also support the use of ADCs. Thus, our study results do
not preclude ADC cancer therapies targeting EphA2 as
yet. Before additional studies are considered, however,
the cause of the AEs observed in this study must be
further explored. Specifically, the MEDI-547 target in
epithelial tissues included in the preclinical human tissue
cross-reactivity study should be identified. If EphA2 is
expressed in these tissues, this would eliminate it as a potential
target for ADC cancer therapies. Alternatively, it is possible
that MEDI-547 may cross react with another protein, perhaps
another Eph family member, again preventing further study of
MEDI-547. An alternate antibody could then be considered
for use as an ADC cancer therapy.
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